{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:28:49Z","timestamp":1787048929386,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41390-025-04552-6","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T18:01:49Z","timestamp":1763143309000},"page":"2687-2693","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of elexacaftor\/tezacaftor\/ivacaftor therapy in children and adolescents with cystic fibrosis and normal spirometry"],"prefix":"10.1038","volume":"99","author":[{"given":"Gianfranco","family":"Alicandro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zazzeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Dolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Cariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Fiandaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Terminiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Innocenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Dacc\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"4552_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","volume":"22","author":"A Lopez","year":"2023","unstructured":"Lopez, A. et al. Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J. Cyst. Fibros. 22, 607\u2013614 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"4552_CR2","volume":"54","author":"V Terlizzi","year":"2024","unstructured":"Terlizzi, V. & Farrell, P. M. Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians. Curr. Probl. Pediatr. Adolesc. Health Care 54, 101637 (2024).","journal-title":"Curr. Probl. Pediatr. Adolesc. Health Care"},{"key":"4552_CR3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton, P. G. et al. Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N. Engl. J. Med. 381, 1809\u20131819 (2019).","journal-title":"N. Engl. J. Med."},{"key":"4552_CR4","doi-asserted-by":"publisher","first-page":"240045","DOI":"10.1183\/16000617.0045-2024","volume":"33","author":"I Fajac","year":"2024","unstructured":"Fajac, I., Burgel, P. R. & Martin, C. New drugs, new challenges in cystic fibrosis care. Eur. Respir. Rev. 33, 240045 (2024).","journal-title":"Eur. Respir. Rev."},{"key":"4552_CR5","doi-asserted-by":"publisher","first-page":"2401178","DOI":"10.1183\/13993003.01178-2024","volume":"64","author":"P Reix","year":"2024","unstructured":"Reix, P. & Chassagnon, G. The younger, the better: lessons learned from real-world studies on CFTR modulators in young children. Eur. Respir. J. 64, 2401178 (2024).","journal-title":"Eur. Respir. J."},{"key":"4552_CR6","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1002\/ppul.27125","volume":"59","author":"V Dacc\u00f2","year":"2024","unstructured":"Dacc\u00f2, V. et al. Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor treatment in children aged 6-11 years with cystic fibrosis in a real-world setting. Pediatr. Pulmonol. 59, 2792\u20132799 (2024).","journal-title":"Pediatr. Pulmonol."},{"key":"4552_CR7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.jcf.2024.04.013","volume":"23","author":"G Alicandro","year":"2024","unstructured":"Alicandro, G. et al. Heterogeneity in response to Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis. J. Cyst. Fibros. 23, 1072\u20131079 (2024).","journal-title":"J. Cyst. Fibros."},{"key":"4552_CR8","doi-asserted-by":"publisher","first-page":"e0292568","DOI":"10.1371\/journal.pone.0292568","volume":"19","author":"AV Piccorelli","year":"2024","unstructured":"Piccorelli, A. V. & Nick, J. A. Modeling cystic fibrosis patient prognosis: Nomograms to predict lung transplantation and survival prior to highly effective modular therapy. PLoS One 19, e0292568 (2024).","journal-title":"PLoS One"},{"key":"4552_CR9","unstructured":"Zolin, A. et al. European Cystic Fibrosis Society Patient Registry (ECFSPR) - Annual Report 2021. www.ecfs.eu\/ecfspr (2023)."},{"key":"4552_CR10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/thoraxjnl-2020-216085","volume":"76","author":"KJ Bayfield","year":"2021","unstructured":"Bayfield, K. J. et al. Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. Thorax 76, 1255\u20131265 (2021).","journal-title":"Thorax"},{"key":"4552_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/BF03344156","volume":"29","author":"E Cacciari","year":"2006","unstructured":"Cacciari, E. et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J. Endocrinol. Invest 29, 581\u2013593 (2006).","journal-title":"J. Endocrinol. Invest"},{"key":"4552_CR12","doi-asserted-by":"crossref","unstructured":"Quanjer, P. H. et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 40, 1324\u20131343 (2012).","DOI":"10.1183\/09031936.00080312"},{"key":"4552_CR13","doi-asserted-by":"crossref","unstructured":"Robinson, P. D. et al. Consensus statement for inert gas washout measurement using multiple- and singlebreath tests. Eur Respir J 41, 507\u2013522 (2013).","DOI":"10.1183\/09031936.00069712"},{"key":"4552_CR14","doi-asserted-by":"crossref","unstructured":"Jensen, R. et al. A systematic approach to multiple breath nitrogen washout test quality. PLoS One 11, e0157523 (2016).","DOI":"10.1371\/journal.pone.0157523"},{"key":"4552_CR15","doi-asserted-by":"publisher","first-page":"2102398","DOI":"10.1183\/13993003.02398-2021","volume":"60","author":"AC Kentgens","year":"2022","unstructured":"Kentgens, A. C. et al. Normative multiple-breath washout data in school-aged children corrected for sensor error. Eur. Respir. J. 60, 2102398 (2022).","journal-title":"Eur. Respir. J."},{"key":"4552_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","volume":"2","author":"TWR Lee","year":"2003","unstructured":"Lee, T. W. R. et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros. 2, 29\u201334 (2003).","journal-title":"J. Cyst. Fibros."},{"key":"4552_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","volume":"23","author":"PR Burgel","year":"2024","unstructured":"Burgel, P. R. et al. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. J. Cyst. Fibros. 23, 187\u2013202 (2024).","journal-title":"J. Cyst. Fibros."},{"key":"4552_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/thx.2006.060889","volume":"62","author":"CH Goss","year":"2007","unstructured":"Goss, C. H. & Burns, J. L. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 62, 360\u2013367 (2007).","journal-title":"Thorax"},{"key":"4552_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","volume":"205","author":"DP Nichols","year":"2022","unstructured":"Nichols, D. P. et al. Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am. J. Respir. Crit. Care Med. 205, 529\u2013539 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4552_CR20","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1513\/AnnalsATS.202401-030RL","volume":"21","author":"K Yaacoby-Bianu","year":"2024","unstructured":"Yaacoby-Bianu, K. et al. Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis with Mildly Decreased and Normal Lung Function: A Real-Life Observational Study. Ann. Am. Thorac. Soc. 21, 1620\u20131623 (2024).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"4552_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jcf.2024.02.001","volume":"23","author":"ET Zemanick","year":"2024","unstructured":"Zemanick, E. T. et al. Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis. J. Cyst. Fibros. 23, 676\u2013684 (2024).","journal-title":"J. Cyst. Fibros."},{"key":"4552_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S2213-2600(24)00407-7","volume":"13","author":"JE Hoppe","year":"2025","unstructured":"Hoppe, J. E. et al. Vanzacaftor\u2013tezacaftor\u2013deutivacaftor for children aged 6\u201311 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir. Med. 13, 244\u2013255 (2025).","journal-title":"Lancet Respir. Med."},{"key":"4552_CR23","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","volume":"206","author":"MA Mall","year":"2022","unstructured":"Mall, M. A. et al. Efficacy and Safety of Elexacaftor\/Tezacaftor\/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. Am. J. Respir. Crit. Care Med. 206, 1361\u20131369 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4552_CR24","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","volume":"208","author":"P McNally","year":"2023","unstructured":"McNally, P. et al. Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor\/Tezacaftor\/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial. Am. J. Respir. Crit. Care Med. 208, 917\u2013929 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4552_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","volume":"22","author":"SJ Schwarzenberg","year":"2023","unstructured":"Schwarzenberg, S. J. et al. Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI. J. Cyst. Fibros. 22, 282\u2013289 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"4552_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","volume":"208","author":"JL Goralski","year":"2023","unstructured":"Goralski, J. L. et al. Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2\u20135 Years with Cystic Fibrosis and at Least One F508del Allele. Am. J. Respir. Crit. Care Med. 208, 59\u201367 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4552_CR27","doi-asserted-by":"publisher","first-page":"2400004","DOI":"10.1183\/13993003.00004-2024","volume":"64","author":"M Stahl","year":"2024","unstructured":"Stahl, M. et al. Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles. Eur. Respir. J. 64, 2400004 (2024).","journal-title":"Eur. Respir. J."},{"key":"4552_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00408-024-00768-1","volume":"203","author":"V Dacc\u00f2","year":"2025","unstructured":"Dacc\u00f2, V. et al. Lung Clearance Index Improves in People with Cystic Fibrosis not Achieving a Clinical Important Difference in Forced Expiratory Volume in One Second After Elexacaftor\/Tezacaftor\/Ivacaftor Therapy. Lung 203, 9 (2025).","journal-title":"Lung"},{"key":"4552_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100690","volume":"32","author":"S Sutharsan","year":"2023","unstructured":"Sutharsan, S. et al. Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg. Heal. Eur. 32, 100690 (2023).","journal-title":"Lancet Reg. Heal. Eur."},{"key":"4552_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","volume":"22","author":"T Lee","year":"2023","unstructured":"Lee, T. et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis. J. Cyst. Fibros. 22, 402\u2013406 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"4552_CR31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/thx.2007.082768","volume":"63","author":"JC Davies","year":"2008","unstructured":"Davies, J. C., Cunningham, S., Alton, E. W. F. W. & Innes, J. A. Lung clearance index in CF: A sensitive marker of lung disease severity. Thorax 63, 96\u201397 (2008).","journal-title":"Thorax"},{"key":"4552_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ppul.26180","volume":"58","author":"BS Frauchiger","year":"2023","unstructured":"Frauchiger, B. S. et al. Variability of clinically measured lung clearance index in children with cystic fibrosis. Pediatr. Pulmonol. 58, 197\u2013205 (2023).","journal-title":"Pediatr. Pulmonol."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04552-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04552-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04552-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:01:10Z","timestamp":1787047270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04552-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4552"],"URL":"https:\/\/doi.org\/10.1038\/s41390-025-04552-6","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"11 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.B. and V.D. report honoraria for lectures and consultancy fees from Vertex Pharmaceuticals.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Written informed consent was obtained from the parents or guardians of the children involved in the study.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Ethics"}}]}}